Neurology 2000;55:1135-1143
© 2000 American Academy of Neurology
Articles
IV immunoglobulin does not reverse established weakness in MS
A double-blind, placebo-controlled trial
J. H. Noseworthy, MD,
P. C. O’Brien, PhD,
B. G. Weinshenker, MD,
J. A. Weis, RN,
T. M. Petterson, MS,
B. J. Erickson, MD,
A. J. Windebank, MD,
J. P. Whisnant, MD,
K. A. Stolp–Smith, MD,
C. M. Harper, Jr., MD,
P. A. Low, MD,
L. J. Romme, BS,
M. Johnson, MS, PT,
K.-N. An, PhD and
M. Rodriguez, MD
From the Departments of Neurology (Drs. Noseworthy, Weinshenker, Windebank, Whisnant, Harper, Low, and Rodriguez, and J.A. Weis), Biostatistics (Dr. O’Brien and T.M. Petterson), Radiology (Dr. Erickson), Physical Medicine and Rehabilitation (Dr. Stolp–Smith), and Orthopedics (Dr. An, L.J. Romme, and M. Johnson), Mayo Clinic, Rochester, MN.
Address correspondence and reprint requests to Dr. John H. Noseworthy, Department of Neurology, Mayo Clinic/Mayo Foundation, 200 First Street, SW, Rochester, MN 55905; e-mail: noseworthy.john{at}mayo.edu
BACKGROUND: Immunoglobulin (Ig) administration induces remyelination in the Theiler’s virus model of MS.
METHODS: A randomized, double-blinded, placebo-controlled trial of IV immunoglobulin (IVIg) was performed in patients with MS who had persistent muscle weakness that had been stable for between 4 and 18 months to determine whether this would improve muscle strength (primary outcome: isometric muscle strength). Patients received either IVIg (0.4 g/kg) or placebo daily for 5 days, then single infusions every 2 weeks for 3 months (total, 11 infusions). Muscle groups identified by clinical measures to have unchanging significant weakness were the major targets for therapeutic response (targeted neurologic deficit [TND]).
RESULTS: IVIg was well tolerated. An interim analysis after 67 patients were enrolled indicated no difference in the degree of change in strength between treatment groups in either the TND or non-TND muscle groups at 6 months, and the trial was terminated. There was no apparent benefit in relapse behavior or impairment measures during the 6-month observation period. Nor was there apparent benefit in either patients who remained clinically stable or in those with evidence of disease activity. Patients with active MS during the trial worsened in both TND and non-TND muscle groups. This worsening was seen regardless of whether the clinical manifestations of disease activity involved the TND muscle groups.
CONCLUSIONS: IVIg does not reverse established weakness in MS. Measurements of isometric muscle strength were reliable (reproducible) indices of strength and may be sensitive, objective methods to document functional changes in impairment in future MS trials.
This article has been cited by other articles:
|
|
|
|
 
W. K. Engel, F. Fazekas, F.D. Lublin, D. Li, M.S. Freedman, H.P. Hartung, P. Rieckmann, P. Soelberg Sorensen, M. Maas-Enriquez, B. Sommerauer, et al.
INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL
Neurology,
September 29, 2009;
73(13):
1077 - 1078.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stangel
Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins
Therapeutic Advances in Neurological Disorders,
September 1, 2008;
1(2):
115 - 124.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. M Gurcan and A R. Ahmed
Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders
Ann. Pharmacother.,
May 1, 2007;
41(5):
812 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger
The value of animal models for drug development in multiple sclerosis
Brain,
August 1, 2006;
129(8):
1940 - 1952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. G. Roed, A. Langkilde, F. Sellebjerg, M. Lauritzen, P. Bang, A. Morup, and J. L. Frederiksen
A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis
Neurology,
March 8, 2005;
64(5):
804 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Soelberg Sorensen, J. Haas, F. Sellebjerg, T. Olsson, M. Ravnborg, and the TARIMS Study Group
IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS
Neurology,
December 14, 2004;
63(11):
2028 - 2033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Dalakas
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA,
May 19, 2004;
291(19):
2367 - 2375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Barkhof, W. Bruck, C. J. A. De Groot, E. Bergers, S. Hulshof, J. Geurts, C. H. Polman, and P. van der Valk
Remyelinated Lesions in Multiple Sclerosis: Magnetic Resonance Image Appearance
Arch Neurol,
August 1, 2003;
60(8):
1073 - 1081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al.
Intravenous immunoglobulin in neurological disease: a specialist review
J. Neurol. Neurosurg. Psychiatry,
April 1, 2002;
72(4):
440 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Stangel and H-P Hartung
Despair of repair
J. Neurol. Neurosurg. Psychiatry,
January 1, 2002;
72(1):
1 - 4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Noseworthy, P. C. O'Brien, T. M. Petterson, J. Weis, L. Stevens, W. K. Peterson, D. Sneve, S. A. Cross, J. A. Leavitt, R. G. Auger, et al.
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Neurology,
June 12, 2001;
56(11):
1514 - 1522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
